CORRECTION

Both cladribine and alemtuzumab may effect MS via B-cell depletion

In the article “Both cladribine and alemtuzumab may effect MS via B-cell depletion” by D. Baker et al.,¹ the title should read “Both cladribine and alemtuzumab may affect MS via B-cell depletion.” The authors regret the error. Additionally, in the key for figure 2 the red diamond should indicate “CLAD 3.5 mg/kg” rather than “CLAD 6.5 mg/kg” as originally published. The editorial staff regret the error.

REFERENCE

1. Baker D, Herrod SS, Alvarez-Gonzalez C, Zalewski L, Albor C, Schmierer K. Both cladribine and alemtuzumab may effect MS via B-cell depletion. *Neurol Neuroimmunol Neuroinflamm* 2017;4:e360.

Neurology® Neuroimmunology & Neuroinflammation

Both cladribine and alemtuzumab may effect MS via B-cell depletion

Neurol Neuroimmunol Neuroinflamm 2017;4;

DOI 10.1212/NXI.0000000000000391

This information is current as of September 7, 2017

**Updated Information &
Services**

including high resolution figures, can be found at:
<http://nn.neurology.org/content/4/5/e391.full.html>

References

This article cites 1 articles, 0 of which you can access for free at:
<http://nn.neurology.org/content/4/5/e391.full.html##ref-list-1>

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
<http://nn.neurology.org/misc/about.xhtml#permissions>

Reprints

Information about ordering reprints can be found online:
<http://nn.neurology.org/misc/addir.xhtml#reprintsus>

Neurol Neuroimmunol Neuroinflamm is an official journal of the American Academy of Neurology. Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright © 2017 American Academy of Neurology. All rights reserved. Online ISSN: 2332-7812.